Literature DB >> 16504759

SRC family kinase inhibitor SU6656 enhances antiangiogenic effect of irradiation.

Kyle C Cuneo1, Ling Geng, Jiahuai Tan, Jeffrey Brousal, Eric T Shinohara, Katherine Osusky, Allie Fu, Yu Shyr, Huiyun Wu, Dennis E Hallahan.   

Abstract

PURPOSE: Src family kinases (SFK) have been identified as molecular targets. SU6656 is a small-molecle indolinone that specifically inhibits this family of kinases. METHODS AND MATERIALS: Human umbilical vein endothelial cells were used to study the effects of SFK inhibition. Western blot analysis was performed to determine the effect of SFK inhibition on the PI3K/Akt pathway and caspase cleavage. Apoptosis was studied by propidium iodide staining of nuclei. Angiogenesis was examined using capillary tubule formation in Matrigel. Tumor response was further studied in vivo using Lewis lung carcinoma cells implanted into the dorsal skin fold of mice in the window model and in the hind limb in the tumor volume model.
RESULTS: Clonogenic survival of endothelial cells was decreased after the combined therapy of SU6656 and radiation compared with radiotherapy alone. Furthermore, SFK inhibition by SU6656 attenuated radiation-induced Akt phosphorylation and increased radiation-induced apoptosis and vascular endothelium destruction. In vivo, SU6656 administered before irradiation significantly enhanced radiation-induced destruction of blood vessels within the tumor windows and enhanced tumor growth delay when administered during fractionated irradiation.
CONCLUSIONS: This study demonstrates the potential use of SFK inhibition to enhance the effects of ionizing radiation during radiotherapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16504759     DOI: 10.1016/j.ijrobp.2005.11.014

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  9 in total

1.  Latent Kaposi's sarcoma-associated herpesvirus infection of endothelial cells activates hypoxia-induced factors.

Authors:  Patrick A Carroll; Heidi L Kenerson; Raymond S Yeung; Michael Lagunoff
Journal:  J Virol       Date:  2006-09-06       Impact factor: 5.103

Review 2.  Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studies.

Authors:  Manmeet S Ahluwalia; John de Groot; Wei Michael Liu; Candece L Gladson
Journal:  Cancer Lett       Date:  2010-12-08       Impact factor: 8.679

3.  Mesenchymal migration as a therapeutic target in glioblastoma.

Authors:  Jessie Zhong; Andre Paul; Stewart J Kellie; Geraldine M O'Neill
Journal:  J Oncol       Date:  2010-06-21       Impact factor: 4.375

4.  Enzastaurin, an inhibitor of PKCbeta, Enhances Antiangiogenic Effects and Cytotoxicity of Radiation against Endothelial Cells.

Authors:  Aaron C Spalding; Benjamin D Zeitlin; Kari Wilder-Romans; Mary E Davis; Jacques E Nor; Theodore S Lawrence; Edgar Ben-Josef
Journal:  Transl Oncol       Date:  2008-12       Impact factor: 4.243

Review 5.  Improving the prognosis for patients with glioblastoma: the rationale for targeting Src.

Authors:  John de Groot; Vanessa Milano
Journal:  J Neurooncol       Date:  2009-05-13       Impact factor: 4.130

6.  FAK deletion promotes p53-mediated induction of p21, DNA-damage responses and radio-resistance in advanced squamous cancer cells.

Authors:  Kathryn Graham; Kim Moran-Jones; Owen J Sansom; Valerie G Brunton; Margaret C Frame
Journal:  PLoS One       Date:  2011-12-14       Impact factor: 3.240

7.  The Effect of Chemoradiotherapy with SRC Tyrosine Kinase Inhibitor, PP2 and Temozolomide on Malignant Glioma Cells In Vitro and In Vivo.

Authors:  Keun-Yong Eom; Bong Jun Cho; Eun Jung Choi; Jin-Ho Kim; Eui Kyu Chie; Hong-Gyun Wu; Il Han Kim; Sun Ha Paek; Jae-Sung Kim; In Ah Kim
Journal:  Cancer Res Treat       Date:  2015-06-04       Impact factor: 4.679

Review 8.  Interfering with Tumor Hypoxia for Radiotherapy Optimization.

Authors:  Irma Telarovic; Roland H Wenger; Martin Pruschy
Journal:  J Exp Clin Cancer Res       Date:  2021-06-21

Review 9.  SRC Kinase in Glioblastoma News from an Old Acquaintance.

Authors:  Claudia Cirotti; Claudia Contadini; Daniela Barilà
Journal:  Cancers (Basel)       Date:  2020-06-12       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.